Efficiency of Immunological Blood Biomarkers in Predicting Chemotherapy Response and Survival Outcome for Non-Targetable Advanced Non-Small Cell Lung Cancer Patients [0.03%]
预测非小细胞肺癌化疗疗效及生存结局的免疫血清标志物灵敏度和特异度研究
Putthapoom Lumjiaktase,Nanthisa Kemawichanurat,Kanthon Santiwiwas et al.
Putthapoom Lumjiaktase et al.
Purpose: Chemotherapy is the main therapy for non-targetable advanced non-small cell lung cancer (NSCLC). Nevertheless, few biomarkers are currently available for predicting clinical outcomes and monitoring treatment resp...
Prospective Observational Real-World Study of Afatinib as First-Line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in China [0.03%]
对中国EGFR突变阳性晚期非小细胞肺癌患者一线使用阿法替尼治疗的前瞻性、观察性、真实世界研究
Jianying Zhou,Yongsheng Wang,Jiewen Peng et al.
Jianying Zhou et al.
Purpose: Approximately 38% of Chinese patients with non-small cell lung cancer (NSCLC) exhibit a mutation in the epidermal growth factor receptor (EGFR) gene. Afatinib, which targets the EGFR, is approved for first-line t...
Reduced Claudin-3 Expression Is Linked to Unfavorable Tumor Features and Poor Prognosis in Non-Small Cell Lung Cancer [0.03%]
Claudin-3低表达与非小细胞肺癌不良预后相关
Nina Schraps,Martin Reck,Birgit Hantzsch-Kuhn et al.
Nina Schraps et al.
Background: Claudin 3 (CLDN3) is a transmembrane protein which forms tight junctions (TJs) together with other claudins, occludin, and junctional adhesion molecules. Because of its membranous localization CLDN3 is a poten...
Incretin Receptor Agonist, Semaglutide, as a Treatment for Alectinib-Induced Excessive Weight Gain. A Case Report [0.03%]
索拉非尼致手足皮肤反应的溻渍疗法护理报告
Alexandria T M Lee,Cathleen June Park,Zhaohui Liao Arter et al.
Alexandria T M Lee et al.
Alectinib is a second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) that has been widely used as first-line (1L) treatment of advanced ALK+ non-small cell lung cancer (NSCLC) ever since its approved indication ...
Integrated Multi-Omics Approaches for Predicting Immune Checkpoint Inhibitor Response in NSCLC - Insights From Genomics, Proteomics, and Metabolomics [0.03%]
基于基因组学、蛋白质组学和代谢组学的非小细胞肺癌免疫检查点抑制剂反应预测的整合多组学方法见解
Eman Elayeh,Shereen M Aleidi,Orwa Aboud et al.
Eman Elayeh et al.
Background and purpose: Immune checkpoint inhibitors (ICIs) have improved outcomes in non-small cell lung cancer (NSCLC), yet durable benefit is limited to a subset of patients. Reliable predictive biomarkers are therefor...
Pulmonary Nodular Lymphoid Hyperplasia: Reviewing a Lung Cancer Mimicker [0.03%]
肺结节样淋巴组织增生症：一种肺癌的鉴別诊断疾病文献复习
Gabriela Schneider Galvão,Jônatas Fávero Prietto Dos Santos,Ying-Han R Hsu et al.
Gabriela Schneider Galvão et al.
Background: Pulmonary nodular lymphoid hyperplasia is a rare benign lymphoproliferative disorder. Patients are commonly asymptomatic. Its radiological presentation is characterized by peripheral single nodular lesion, mul...
A Concise Review of the Approved MET TKIs (Savolitinib, Gumarontinib, Vebreltinib, Tepotinib, Capmatinib) in China for MET Exon 14 Splice Site Mutated (METex14+) NSCLC Circa 2025 [0.03%]
中国获批的MET TKIs（萨沃利替尼、谷美替尼、维布替尼、特泊替尼、卡马替尼）用于MET外显子14跳变（METex14+）NSCLC治疗的简明回顾（截至2025年）
Yanyan Hu,Sai-Hong Ignatius Ou
Yanyan Hu
Splice site mutations around or within exon 14 of MET (METex14+) are rare, but are one of the common actionable driver mutations in elderly patients with non-small cell lung cancer (NSCLC). Globally, only two MET tyrosine kinase inhibitors ...
Successful and On-going Long-Term Disease Control (>24 Months) with Gilteritinib in an ALK+ NSCLC Patient with Brain Metastasis Who Has Progressed on Multiple ALK TKIs. A Case Report and Review of Literature on Gilteritnib [0.03%]
克唑替尼、阿来替尼和塞瑞替尼序贯耐药后，Gilteritinib治疗伴脑转移的ALK+NSCLC患者的长期疗效：一例报告及Gilteritinib治疗文献回顾
Sai-Hong Ignatius Ou,Cathleen June Park,Zhaohui Liao Arter et al.
Sai-Hong Ignatius Ou et al.
Background: Despite the approval to date of 3 generations of ALK tyrosine kinase inhibitors (TKIs) and the clinical development of a 4th-generation ALK TKI, neladalkib (NVL-655), patients still eventually progress on sequ...
Gina N Duronio,Julien Sage
Gina N Duronio
The heterogeneous nature of cell populations in human tumors is a major contributor to tumor evolution, including and perhaps most importantly in response to treatment. Here, we review current knowledge on tumor heterogeneity and cell state...
Jing Wang,Layana Biglow,Megan Baumgart
Jing Wang
The identification of molecular driver mutations in non-small cell lung cancer (NSCLC) has changed the therapeutic landscape for this disease. Over the last 20 years, a growing number of driver mutations have been identified in addition to ...